Seek and You Will Find: A Prospective Case-Finding Study for the Detection of Neisseria gonorrhoeae Xpert® CT/NG Diagnostic Escape Mutants in England

Objectives: In 2025, the UK Health Security Agency (UKHSA), confirmed the identification of a Neisseria gonorrhoeae (NG) diagnostic escape mutant for the Xpert® CT/NG assay (Cepheid). Subsequently, a small number of further mutants were reported internationally. The assay comprises two NG-specific targets, NG2 and NG4, and amplification is required in both to report a positive result. This prospective case-finding study aimed to investigate the presence of diagnostic escape mutants in NG-negative specimens from two sexual health services using the Xpert® CT/NG assay to provide in-clinic testing. Methods: Residual Xpert® NG-negative clinical specimens were collected during December 2025 and transferred to the national STI Reference Laboratory at UKHSA. Following anonymisation extracts were tested on the GeneProofTM Neisseria gonorrhoeae PCR kit (GeneProof). GeneProofTM NG-positive specimens were re-tested on the Xpert®CT/NG assay to confirm. Results: In total, 978 specimens were tested on the GeneProofTM assay; 99.7% (975/978) were confirmed as NG-negative. Three specimens (two rectal swabs and one urine sample) tested NG-positive on the GeneProofTM assay. Two specimens were re-tested on the Xpert® CT/NG assay, both re-tested NG-negative. Both samples amplified either the NG2 or NG4 target within the Xpert® NG assay, but not both targets required for a positive result. The remaining sample was insufficient for re-testing. An extrapolation of possible missed NG cases due to mutants, indicated that between 62 and 562 cases may have been missed in 2025 from these clinics. Conclusions: This prospective case-finding study demonstrated excellent sensitivity of the Xpert® CT/NG assay with 99.7% of NG-negative samples correctly identified. However, a small number of diagnostic escape mutants were detected, and extrapolation suggests there may be some degree of missed cases from providers using this assay as a near-patient test. Further work is required to fully understand the prevalence of the mutants and clinical implications of missed diagnoses.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.11.26367844
Primary Topic
Reproductive tract infections research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Seek and You Will Find: A Prospective Case-Finding Study for the Detection of Neisseria gonorrhoeae Xpert® CT/NG Diagnostic Escape Mutants in England

Derren R Ready, Laura Viviani, Melissa J. Jansen van Rensburg, Katy Sinka et al.
medRxiv
Reproductive tract infections research
preprint

Seek and You Will Find: A Prospective Case-Finding Study for the Detection of Neisseria gonorrhoeae Xpert® CT/NG Diagnostic Escape Mutants in England

Derren R Ready, Laura Viviani, Melissa J. Jansen van Rensburg, Katy Sinka, Michael Rayment, Gary George Whitlock, Marcus James Pond, Rachel Pitt, Sarah Alexander, Helen Fifer, Miriam O’Connor, Ella Finnie, Malika Koulmi
preprint en

Abstract

Objectives: In 2025, the UK Health Security Agency (UKHSA), confirmed the identification of a Neisseria gonorrhoeae (NG) diagnostic escape mutant for the Xpert® CT/NG assay (Cepheid). Subsequently, a small number of further mutants were reported internationally. The assay comprises two NG-specific targets, NG2 and NG4, and amplification is required in both to report a positive result. This prospective case-finding study aimed to investigate the presence of diagnostic escape mutants in NG-negative specimens from two sexual health services using the Xpert® CT/NG assay to provide in-clinic testing. Methods: Residual Xpert® NG-negative clinical specimens were collected during December 2025 and transferred to the national STI Reference Laboratory at UKHSA. Following anonymisation extracts were tested on the GeneProofTM Neisseria gonorrhoeae PCR kit (GeneProof). GeneProofTM NG-positive specimens were re-tested on the Xpert®CT/NG assay to confirm. Results: In total, 978 specimens were tested on the GeneProofTM assay; 99.7% (975/978) were confirmed as NG-negative. Three specimens (two rectal swabs and one urine sample) tested NG-positive on the GeneProofTM assay. Two specimens were re-tested on the Xpert® CT/NG assay, both re-tested NG-negative. Both samples amplified either the NG2 or NG4 target within the Xpert® NG assay, but not both targets required for a positive result. The remaining sample was insufficient for re-testing. An extrapolation of possible missed NG cases due to mutants, indicated that between 62 and 562 cases may have been missed in 2025 from these clinics. Conclusions: This prospective case-finding study demonstrated excellent sensitivity of the Xpert® CT/NG assay with 99.7% of NG-negative samples correctly identified. However, a small number of diagnostic escape mutants were detected, and extrapolation suggests there may be some degree of missed cases from providers using this assay as a near-patient test. Further work is required to fully understand the prevalence of the mutants and clinical implications of missed diagnoses.

medRxiv
Imperial College Healthcare NHS Trust (GB), Chelsea and Westminster Hospital NHS Foundation Trust (GB), UK Health Security Agency (GB)
Good health and well-being
Reproductive tract infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon